Published in J Clin Endocrinol Metab on February 23, 2011
Surgical approach to medullary thyroid carcinoma associated with multiple endocrine neoplasia type 2. Clinics (Sao Paulo) (2012) 0.86
Calcitonin estimation in patients with nodular goiter and its significance for early detection of MTC: european comments to the guidelines of the American Thyroid Association. Thyroid Res (2013) 0.83
A Genomic Alternative to Identify Medullary Thyroid Cancer Preoperatively in Thyroid Nodules with Indeterminate Cytology. Thyroid (2016) 0.75
Arriving at the Right Diagnosis in an Era of Precision Medicine. Case Rep Oncol (2016) 0.75
Association of the preoperative neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios with lymph node metastasis and recurrence in patients with medullary thyroid carcinoma. Medicine (Baltimore) (2016) 0.75
An evaluation of the diagnostic efficacy of fine needle aspiration biopsy in patients operated for a thyroid nodular goiter. Onco Targets Ther (2016) 0.75
RET mutation p.S891A in a Chinese family with familial medullary thyroid carcinoma and associated cutaneous amyloidosis binding OSMR variant p.G513D. Oncotarget (2015) 0.75
Axillary Lymph Node Metastasis in Medullary Thyroid Carcinoma: A Case Report. Iran J Otorhinolaryngol (2017) 0.75
Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid (2009) 35.34
Circulating mutant DNA to assess tumor dynamics. Nat Med (2007) 10.33
Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid (2009) 10.20
Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med (1994) 8.39
Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med (2003) 3.94
Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. J Clin Endocrinol Metab (2006) 2.81
Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer (2006) 2.73
Shear wave elastography: a new ultrasound imaging mode for the differential diagnosis of benign and malignant thyroid nodules. J Clin Endocrinol Metab (2010) 2.29
Interest of routine measurement of serum calcitonin: study in a large series of thyroidectomized patients. The French Medullary Study Group. J Clin Endocrinol Metab (1997) 2.25
Fine-needle aspiration may miss a third of all malignancy in palpable thyroid nodules: a comprehensive literature review. Ann Surg (2007) 2.19
Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab (1994) 2.05
Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab (2004) 1.82
Usefulness of fine-needle aspiration in the diagnosis of thyroid carcinoma: a retrospective study in 37,895 patients. Cancer (2000) 1.80
Malignancy risk for fine-needle aspiration of thyroid lesions according to the Bethesda System for Reporting Thyroid Cytopathology. Am J Clin Pathol (2010) 1.80
Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer (2000) 1.73
Prevalence of sporadic medullary thyroid carcinoma: the importance of routine measurement of serum calcitonin in the diagnostic evaluation of thyroid nodules. Clin Endocrinol (Oxf) (1995) 1.70
Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endocrinol Metab (2005) 1.50
Real-time ultrasound elastography in the differential diagnosis of benign and malignant thyroid nodules. J Ultrasound Med (2009) 1.43
Surgical treatment of thyroid cancers with concurrent Graves disease. Ann Surg Oncol (2004) 1.43
American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules: Executive Summary of recommendations. J Endocrinol Invest (2010) 1.40
The incidence of thyroid carcinoma in multinodular goiter: retrospective analysis. Acta Biomed (2004) 1.30
Pheochromocytomas and anesthesia. Int Anesthesiol Clin (1997) 1.23
Calcitonin measurement in the evaluation of thyroid nodules in the United States: a cost-effectiveness and decision analysis. J Clin Endocrinol Metab (2008) 1.23
Potency and tolerance of calcitonin stimulation with high-dose calcium versus pentagastrin in normal adults. J Clin Endocrinol Metab (2009) 1.20
Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J Clin Endocrinol Metab (2003) 1.17
Routine measurement of serum calcitonin is useful for early detection of medullary thyroid carcinoma in patients with nodular thyroid diseases. Thyroid (2001) 1.16
Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab (1996) 1.15
Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma. Clinics (Sao Paulo) (2009) 1.11
Biomarker-based risk stratification for previously untreated medullary thyroid cancer. J Clin Endocrinol Metab (2010) 1.11
Adverse drug reactions in patients with phaeochromocytoma: incidence, prevention and management. Drug Saf (2007) 1.10
The change in surgical practice from subtotal to near-total or total thyroidectomy in the treatment of patients with benign multinodular goiter. World J Surg (2009) 1.08
Surgical treatment of medullary thyroid carcinoma. J Intern Med (2003) 1.04
Ultrasonographic findings of medullary thyroid carcinoma: a comparison with papillary thyroid carcinoma. Korean J Radiol (2009) 1.01
Evaluation of routine basal serum calcitonin measurement for early diagnosis of medullary thyroid carcinoma in seven hundred seventy-three patients with nodular goiter. Thyroid (1999) 1.00
[Incidental thyroid carcinoma: a multicentric experience]. Recenti Prog Med (2010) 0.95
Diagnostic pitfalls in thyroid fine-needle aspiration: a review of 394 cases. Diagn Cytopathol (1993) 0.94
Concurrent occurrence of medullary thyroid carcinoma and papillary thyroid carcinoma in the same thyroid should be considered as coincidental. Clin Endocrinol (Oxf) (2010) 0.94
Thyroid cancer in toxic and non-toxic multinodular goiter. J Postgrad Med (2007) 0.93
The prevalence of occult medullary thyroid carcinoma at autopsy. J Clin Endocrinol Metab (2010) 0.92
Preoperative diagnosis of medullary thyroid carcinoma by RT-PCR using RNA extracted from leftover cells within a needle used for fine needle aspiration biopsy. J Clin Endocrinol Metab (1999) 0.91
Preoperative diagnosis of medullary thyroid carcinoma: fine needle aspiration cytology as compared with serum calcitonin measurement. J Surg Oncol (2005) 0.90
Medullary thyroid carcinoma: comparison with papillary thyroid carcinoma and application of current sonographic criteria. AJR Am J Roentgenol (2010) 0.89
American Thyroid Association guidelines for management of medullary thyroid cancer: an adult endocrinology perspective. Thyroid (2009) 0.89
Incidental occult carcinomas in total thyroidectomy for benign diseases of the thyroid. Ceylon Med J (2009) 0.87
Medullary thyroid carcinoma: pitfalls in diagnosis by fine needle aspiration cytology and relationship of cytomorphology to RET proto-oncogene mutations. Acta Cytol (2005) 0.86
[Cancer in multinodular goiter]. Ann Ital Chir (1997) 0.86
Medullary thyroid carcinoma: an accurate pre-operative diagnosis by reverse transcription-PCR. Eur J Endocrinol (2000) 0.84
Medullary and papillary tumors are frequently associated in the same thyroid gland without evidence of reciprocal influence in their biologic behavior. Thyroid (2004) 0.83
Thyroid incidentalomas: prediction of malignancy and management. Int Surg (2006) 0.83
Importance of gender-specific calcitonin thresholds in screening for occult sporadic medullary thyroid cancer. Endocr Relat Cancer (2009) 0.82
Surgical approach to medullary thyroid cancer. Arq Bras Endocrinol Metabol (2007) 0.82
Cytologic diagnosis of medullary carcinoma of the thyroid gland. Diagn Cytopathol (2000) 0.81
[Thyroid nodular pathology: retrospective study of 917 surgical interventions]. Chir Ital (1981) 0.76
Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell (2003) 5.36
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol (2011) 3.31
Notch inhibits Ptf1 function and acinar cell differentiation in developing mouse and zebrafish pancreas. Development (2004) 2.21
Thyroid carcinoma. J Natl Compr Canc Netw (2010) 2.02
Notch in lung development and lung cancer. Semin Cancer Biol (2004) 1.73
Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells. Cancer Res (2006) 1.65
Achaete-scute complex homologue 1 regulates tumor-initiating capacity in human small cell lung cancer. Cancer Res (2009) 1.55
Inhibiting the cyclin-dependent kinase CDK5 blocks pancreatic cancer formation and progression through the suppression of Ras-Ral signaling. Cancer Res (2010) 1.54
Notch signaling induces rapid degradation of achaete-scute homolog 1. Mol Cell Biol (2002) 1.51
The Ras/Raf/MEK/extracellular signal-regulated kinase pathway induces autocrine-paracrine growth inhibition via the leukemia inhibitory factor/JAK/STAT pathway. Mol Cell Biol (2003) 1.44
Regulation of neuroendocrine differentiation in gastrointestinal carcinoid tumor cells by notch signaling. J Clin Endocrinol Metab (2005) 1.39
Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer. J Clin Endocrinol Metab (2009) 1.38
NCCN task force: clinical utility of PET in a variety of tumor types. J Natl Compr Canc Netw (2009) 1.24
Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. J Clin Endocrinol Metab (2012) 1.21
Thyroid carcinoma. J Natl Compr Canc Netw (2007) 1.13
Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer. Clin Cancer Res (2011) 1.13
Thyroid carcinoma. J Natl Compr Canc Netw (2005) 1.04
Insights into the achaete-scute homolog-1 gene (hASH1) in normal and neoplastic human lung. Lung Cancer (2012) 0.98
Medullary carcinoma. J Natl Compr Canc Netw (2010) 0.97
CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth. Cancer Res (2003) 0.96
Interleukin-1beta can mediate growth arrest and differentiation via the leukemia inhibitory factor/JAK/STAT pathway in medullary thyroid carcinoma cells. Cytokine (2004) 0.92
American Thyroid Association guidelines for management of medullary thyroid cancer: an adult endocrinology perspective. Thyroid (2009) 0.89
Selectively targeting mutant BRAF in thyroid cancer. J Clin Endocrinol Metab (2010) 0.85
GDNF-induced leukemia inhibitory factor can mediate differentiation via the MEK/ERK pathway in pheochromocytoma cells derived from nf1-heterozygous knockout mice. Exp Cell Res (2005) 0.83
Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer. J Clin Endocrinol Metab (2005) 0.82
Notch in malignancy. Cancer Treat Res (2003) 0.82
Unusual case of metastatic neuroendocrine tumor. Endocr Pract (2007) 0.79
Anaplastic Thyroid Carcinoma, Version 2.2015. J Natl Compr Canc Netw (2015) 0.78
Serendipity in the diagnosis of pheochromocytoma. J Comput Assist Tomogr (2013) 0.75